A recent publication from Berger and colleagues evaluated the proteomic changes in the CSF of AD Neuroimaging Initiative (ADNI) samples by applying linear regression models adjusted by age, sex, APOE4 copy number, and linear models to adjust by AD clinical status or CSF levels of Aβ or tau. Here, MAPT is linked to Alzheimer disease.